We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > KEYNOTE-590

News List

FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma americanpharmaceuticalreview
March 26, 2021
The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or ...
Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial pharmaceutical-business-review
September 27, 2020
Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients ...